Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for bismuth subcitrate potassium / metronidazole / tetracycline, the scientific conclusions are as follows:

In view of available data on cerebellar syndrome from the literature, and spontaneous reports including in some cases a close temporal relationship, and a positive de-challenge, the Lead Member State considers a causal relationship between bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride and cerebellar syndrome is at least a reasonable possibility. The Lead Member State concluded that the product information of products containing bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride should be amended accordingly.

Having reviewed the PRAC recommendation, the CMDh agrees with the PRAC overall conclusions and grounds for recommendation.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for bismuth subcitrate potassium / metronidazole / tetracycline the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing bismuth subcitrate potassium / metronidazole / tetracycline is unchanged subject to the proposed changes to the product information

The CMDh recommends that the terms of the marketing authorisation(s) should be varied.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **<u>underlined and in bold</u>**, deleted text ~~strike through~~)>

Summary of Product Characteristics

- Section 4.8

b. Tabulated list of adverse reactions

The following adverse reaction should be added under the SOC Nervous system disorders with a frequency Not known:

PT Cerebellar syndrome

c. Description of selected adverse reactions

Cerebellar syndrome (eg. ataxia, dysarthria, gait impairment, nystagmus and tremor), which may resolve upon discontinuation of the drug, have been observed with Pylera.

Package Leaflet

Section 4 Possible side effects

Not known (cannot be estimated from the available data)

Neurological disorder called cerebellar syndrome, which symptoms can include difficulties in coordinating movements, speaking and/or walking, involuntary movement of the eyes, and shaking. It may resolve upon stopping the treatment.

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	30 January 2025 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	16 March 2025
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	15 May 2025